Extracorporeal Shock Wave Therapy in Patients with Plantar Fasciitis

Effects of Extracorporeal Shock Wave Therapy on Pain and Ultrasonographic Findings in Adult Patients with Plantar Fasciitis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012072910439N1

Enrollment

Registered

2012-08-17

Start date

2010-06-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plantar Fasciitis. Plantar fascial fibromatosis

Interventions

Intervention 1: Intervention: ESWT by weekly interval for three consecutive weeks

2000 focused shock waves and 2000 radial pulses in three sessions (4000 shock waves/session of 0.2 mJ/mm2) at weekly intervals. Intervention 2: Placebo: Sham treatment was done where standard contact

Treatment - Other

Placebo

Intervention: ESWT by weekly interval for three consecutive weeks

2000 focused shock waves and 2000 radial pulses in three sessions (4000 shock waves/session of 0.2 mJ/mm2) at weekly intervals.

Placebo: Sham treatment was done where standard contact of radial and focus probe with the skin was avoided. The machine makes a noise with every shock wave delivered and, in order to enhance the sha

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusions criteria: - Age 18 to 65 years - Having plantar heel pain for at least three months and point tenderness at or near the medial calcaneal insertion of the plantar fascia, - Have no satisfactory response to common treatments such as NSAIDs and physiotherapy - Willing to participate Exclusion criteria: - Having diabetes, additional foot or ankle pathology (including instability, arthritis, generalized polyarthritis, diffuse heel pad tenderness), local dermatological problems, neurological abnormalities, history of recent trauma or foot surgery, connective tissue or infectious diseases, malignancy, or vasculitis, - Pregnant patients, - Those who received anticoagulant therapy in the preceding six months

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Plantar Fascia Thickness. Timepoint: Before and 12 weeks after therapy. Method of measurement: Ultrasonograpgy.	—

Secondary

Measure	Time frame
Pain. Timepoint: Before and 12 weeks after therapy. Method of measurement: Numerical rating scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Sepideh Sajadieh

Isfahan University of Medical Sciences

sepidehsajadieh@yahoo.com+98 31 1220 6221

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026